好的好的好的，好的，

行的行。

as well as a professor grapa grocery from from the understanding hospital to make the opening remarks respectively。

firstly， a birth introduction about a professor ong professssone is from the dedepartment of himatthology riing hospitital shhahajon university school of medicine to physician facctor advisor to adminiuraate yon yrecor or of hospital， and also national outstanding young physicipopoctor， or felof of french institute of how the medical research。

so firstly， please welcome prostisor。

so distinguh prodical reseech and or distinguish professor underline line。

good email。

am anyone from readating hospital。

it's my honor tomoderate this conconference with prefegrewe this conference。

we are focused on defuse large beselforforespecispecially refocused and refresher patients。

and today， i also i have consulted consulrerefrespatients。

and as these periods for these refgpatients tips， they will have a poor proonnosbut when all the agenpoor or or fic antibodies， and they have ruin。

better prognosses and better responses for this refreleory and relarelapsed diflose large beselling farmers。

so we are very glad。

we have invited professor greg， the principle investigators of the gstter。

so we can we can discuss with the with professor aggreg with these specific antilies in these fields。

and now uum， i'm glad to introduce professor greg。

请翻译一下grad教授disdisfic CV of a professor gredprofessor gred was prprinciple investigator of the staarglore studies and focusing on the progonnosis。

and he arch research。

and here's the culture of informer working party of australian nokimia informer group。

so we are welcome professor greeg to have the。

thank you for that very induduuuyourself colleagues and and and really great tepainand and eme h oreeity to discuss one of my favorite activities is discussing and of the patiof papasiinbecause， as many of of of the mato inof in the pasior， the majority of our discussitions。

so tracto get get as papaents ts， which acacget this papapations tions that acknowledge wasn't going to cure the majority patients and many of of papatients and really great papasitions。

and and we have great discussions and look at the aaof of pavvof of of lve， one of next reciartions tions II cing in a veand。

to unshare，the other one to slide can。

so we could don't share those those slides place。

so i can share my。

a华sject。

好，谢谢佳维思格雷格利教授的。

okay。

thank you。

professor correct for your opening remarks。

so before you formally begin your lecture well at this time， we hope that each of the the analalst and speakers online， please please turn on your camera。

we would have a group photo。

so please turn on your timer and see uh， right？ look look at the camera and three two one。

好，ok。

谢谢各位。

thank you。

thank you all。

thank you all for your participation。

and at the next time would formally enter the first session that is uh some of the thsand ideas internationally incluthe international studies。

so next， we would invite professor grasa gregory， so give us a presentation， the topic of the few stge bees， il and former， including australian research and summary of the starklow study。

so next is welcome。

professor gregrek。

thank you very very much again for the kind introduction。

now i will share the screen， and i might just test again to say。

that we have the current。

us by three。

你暂时be sharing。

the appropriate screen， not impresstative， but just the appropriate slides。

IHT health。

academic uh authand stuc uh uh h say uh look for to cussion。

as introduced my role is roal roerity ity research of understand hohospspspal， where as well as my lima indications。

professor or one national unia city has mentioned， i do code chair and them on the scientific adviserory committee of auaustrlation looking um employment group， which is our cp preative research group。

uh， and i'm um supported by the national autommeticical research council as a funded investigator。

i do have some conflicts of interest sts disployese。

i do have advisory rules to number of industry part， as including rosh gendentic uh， and my institute has ressaved research funding for translation exsuch activities。

mk k one at VNI engine in the past。

so the presentation is not going to break into three categories broadly。

the first is per the introduction。

uh， addressing just the younoung mneeding research refactch and really relarent refactory ory of ularprehensitional research。

i will to focusing refacreoruh really a snapshot of what our current research is in aggressive informs and going to focus on industry sponsorred studies。

and the purpose of this， what i'm going to focus on is some of the translational research and academic research。

that's being performed through groups like our stculaon informer group uh， and then to to ally address what the unmit of this funding landscain australia is and try to present inform studies， often with a uh uh comprehensive translational research， fh。

and then toward the end of present， on the staar gud study， focusing mostly on three infollow up data， which was actually mcently published adrefactor。

uh just。

so fitously， i'm mitnaid in relapse in a factory to you， slade。

they sell in final。

will know deal basic al as the most。

aggressive former characterzze by eets of ofoffacfacfacing noto to to to to inininlinininor extrainvve rereren inininininininreresusuand sshirum。

clinic just this way can is we would hope to at leleall motherlalatest industry， a complete remission or in ar。

so really highlighting that our patients uvery very different patibal sometimes to trade。

australia is a population about twenty milmilers around national trareal comusidof australia deal basase on australia， about three thousand cases， paranms very small numbers compared to to your numbmbers in australia， according to our um national registry， the australian relarelated diststreregistry made in age of primary presentation is around sixty ideas。

so this is a very recent presentation。

uh， american groups， uh publishing blood vance， ces just last month as well。

and the reason i how ght this is can provides quite a nice sigably， the the giinging in a ictory deal VCO。

we don't have to look that hard of the registatory ory al raterity that uknow we have farely ly。

we have be save criteria。

uh alligigiility for atiterthe patients。

uh can now safecartitic。

that would have been eligible for the great stranging criteria of the registrational studies we we have in the US were still sasame with a still tordeal stutience， who would seemingly be eliereritactually tually tting tting cating。

so on the left hility for catdown of how patients is a liitsitin in ltiths， if on the progreswith revgonthof first line， they are be studiying according to the u of。

unas， you can say， if you are a kog is of a higher， a kog of the majority patients are actually dying within opplmonsive progression um and as you can say down the bottom right with initial， if i can actually。

presents， i。

don't know this it it。

it is um um fid population is no second d um papatience were clearly fit the only one es same to have a fair proportion。

patience。

ts they become to highlight really is is faa liability according ding the ererso。

so we we faa available in thirthird， um following the initial early face studies around about the erthe， third and and ah ah starting to say， patigetting third line and therely， then the seconarting to be available after transform studies。

still the titient stuarting to be available a lilad d second pastudies。

what's really important？those， if we look at patience， who would seeingly be paligible retrospected analysis before mlspu sisite， you can say， here of the patience， ts would be clearly ly de seconsecond， and they rest of a small proportion that laluve ve sad ua， a trasisasavvoves novel therapies， which includes for purposes of these body， drug， paenence and others， and other other thereraps vovove， the novel ervolve and other ligibility for study tratrade， including catiis volve novthe purints。

so we totally have a small trainment。

now the scholar one study was canada from canada。

this was was to look at how forforcycseseseseseasproprior al seal al didisease with formore al al al dididiininininstdidiin ininable didisease diprogrein or inreinind ororgraptive analropwas。

of的二vasp。

so now we move to a better a ggof of， and this a figure you ofofpresenented different versision。

this is essensenally adaptive from rethe， the the the ent ent of ent of of ty councounin in TT abut。

now we ed on the activity of county tive preominintly for patients in the second line progress， ss， with the ent ent of primary ertherainin terof of anvity of care orvand and the the other ct of of patient ent， the left perperent of primaaints， the in ct， t of TD and australiand， and in county of countient ts inligitive of of ererapaand auorty ty。

and this on percd in from australiwe have acseseelty t line assessment， sasave will get paent ent aaent ent the ent perpercent patients patitially of patiinent。

progressing only that twenty percent accurrently still be miwith cuate in the second line。

if we take patience who provirest beyond the year that one quarter of patients， as we know you， the agent moabilities many of these patients in eligible for intensified， or can not acacafor atity or and of those， we hainadequate response and moved autographh， that is minminority patients。

if you add up or exside that the bottom the left projected cuure from caty bottom of the promotive cuure from autographed， only saying about one in four patients with proresresses would lost self being inffemiddle is still says a huge unauto to address， says a huge in the middle is you。

so where treatatments are the patients who cannot access cty or legitive for t or or anot auagraatt， or have an adequate response through autographh providing options。

and again， highghlight are the patitits that we will largely patients only five years ago prior to treatments， including。

drag dragts and by specific antibodies， moving through the clnical triland skype to registration。

looks like today。

so just a moment just to reflect on why uh treatments have now become standards of care， second line cart。

so therapfor patients progressing within twelve months based on these two pivoal registrational studies in the seven stustudy exc cell。

uh transfortion study of point， both positive for their primaof approvace survival。

uh， the standard of care at the time being， the viage an augragraphuh was without any briding therapy for the cart recipients。

uh and the later overall survival benefit observed in the particularly the of dims， seven seven， uh registrational uprovval rainstment in australia。

in the red hand side in the thery auaugragrah， that becomcomless less tiless moas。

we have more patitits moving to talk about now， study to say， papatients moving in the reffct reffct inininininto to of patitients graform。

if refleoften and talk about the coral study， the partmer study and similar studies， but it's important of patients。

ts ofofoften go that up to a half of papatits。

these studies recforform p to their padies recpermaing。

we into t hts。

ts， the papatits ts offorthe， the the siininit we have to have a patients forving ing， if that halof of patience， ts ining ing， the the inm and specifificuh。

uh the ones ones surexample。

importantly， though， we assing improved elements of getting patients to a date response， one of many limitations about getting patients to autographh is actually having adequate response to the plant of containsadies， indicating teminsensitivity indicted inaraform。

we we fully getting studidies the early analyssaid inpresented inaraforform。

we be enining patisiwith， the the aaaatatative aaamm incomination with a commenly used the containing savge rererererererese， as actually you did very impressive overall and complete response rates， which suggest that we are getting more patients response to the opefully getting more patients。

and h opportity tive of a se with the odempconof soliwith， the we don't have lly getting studidies is earearly inpadidiwere perforform， the adiority of patience ts dithis yet。

tolerate two， the tray cycles without prohibit of toxic cities and moves through autographh。

so this does suggest the addition of by specific antibobodies may actually improve the um debt of response and get more patients to or told it this transplrent。

so about came， ththerapthis was a comparaprepreviousof patienso intensification of eligible ineligible for planting containing salvinterinterorgraphh。

um this is the largest of the face stustudies loolook at retax of jm s um um get a to ququarof patience ts。

but as can see here here， um is a quarter patience s um second DD thirthird d weeweely with second weekly for this one。

but there was a siarter chatience CR that about half the patients for saving second weekenafter。

this third d weekly with comparable outcomes。

but as you can say， here again filing the majority of sion， we might get up to a quarter patience c um um responsponse h second ty percof overall， but about a quarter patia c um but they usually not jurable with majority of patients proreressing to a quthof of complations。

sounto buy specic guarantee bodies because that's really the the main point of a liverver between inautuate with landscape now。

um there come come a vout， the time dedevelopment and dedeuing the specificc in terms。

and it is important that that that that they they specificc that body dibbelbetwtween of the different specifibility terterms of chedual terterms of int t specifithat for cinfor sometime。

i counthe apdies。

now why always so excited about initially the studidies um particiption in prosisisitridies that that that be be be available， but the inon on ansireredies um bsiing reresiin in is double ble ility of comcompleresponse。

it's important to dies es to progress ss impimpant of oraninstudidium， um sid of patients that plem rethat y that was a reasonable proportion patients， a double hipleinresithat that sisisisisision on reresithat without any of tritridithat would in a countries that h。

australia， we're able to access uh by speto beagain anybodies because we didn't have any good comparior available at the time。

moving into moving。

the second consider be exexamand h。

we momthat momdo that acacmenmibefore。

over the last only decade， particularly the number of research networks we have been using has expanded historically um um groups。

i guess， wewould say， uh， the the ALG or the australition of the fformer group， which is not for profit academic research group， the mabotom of uh active clinical trial investigators in australia at size um HTT in the reararch p， through that a lot of research group where we perform um the institutional clinical trips down the bottom of the right。

we have a very strong consumer um twtworum um bottom for research suppuh and the very good， particularly with the consumer um engagement education for patients， patient ts support。

but through that， a lot of patirelation outtida， the ladip into the able to trtract with。

actively on very volful ful education in that network very important place。

at totop left two of the regiries of one one area that all had had on institutions。

but this， on the ft ininforment， relareladidisease redistmarinddiininininench ininbecause of provide ininasasredidisees registriwhich， c ininmimac CI ldimisisis mullpspespect incomum。

how are doing against which um maininmainatatand similar the sinininininreinand to to the ininaustrinment？

this is a very new again， basically develovelopthis networks。

investigators can quesquestions tions and ofexamof inininininictions and ofexaminininininininininininct a britiggrourouis been acbeen by the ttm prorouabout very active。

translation research programs， uh， i'm involve many， many of money uniyou underststthe hospital particular lar at time， but doing try with crime quequeins land and pafemac significantly。

also， that's how we can make sure we're doing very um i guess， informative transtion research that can wer us ansto to answer wer to answer some the questions。

so these are few the studies that i just going going menmened in terms of addressing some of the needs that we still say in australia um and walk through the one of the time， but essentially be clarifiy trial of uh， looking at study withas， an earlier by the catain in first treatment failure， the apple cut study， which is a very exciting study looking at um by specific ity bodies， a patients who， uh in a remission or pet remission。

close carty。

but i'm a depositive to say if we can selvige patients without a specific ralaabse。

the blocks investigatfor that that looking h and menmention as well。

so starting to clarify clarify again， just to siset the same。

we can currently access in australia in many areas， um aci sell by stuoffers in the seven study in in many jjurisdictions。

uh， your US of seta also a avable able basston transform。

but as we know of studies patients to be eligible for these treatments made to have clinical。

progression within twelve months of their last systemic therapy。

so there are our patients who are not in a clinical emission， still laugh their familila therapy。

now we also know that we getting to the point where we can some reabcatory diababarory didiagnostis this h acal， a glud saragmplplummdim es um optitizthis this this this， that that that that that dgragnn NNA and the a brothe blood DNA was that from the blood samples。

study studn i。

who are being monitored blindly based on symptoms and or a blood test。

not often having scans retain me anymore， but taking up a lot of clinic spice when we really should be moving earlier doing these tids saying you acuate getting these SS out validated and more broadly available。

and then being able to move on to other aspethat， they care like survivation care。

so the clarifying study being led by joshua tiven and early korean investigator um the university queensland and princiof andandasschool in brisbane is a face to study， looking at titient undergoing standard front line therapy， who are recruiting patience are very early presentation。

we're doing a sususuy to idenffy to to define the seconculthe second n pststandard of cait a canicict。

the inmove to a erapy ints， we don't count tly a ericics or ppt pitictest ts during that induction therapy patients， a cicict DNNN and the the ve the a city d ics around the canaics c city DNISAAA licthat。

well， we call all real al DN resulllt， the the the again and then to move through the patience， indicate the intreina DNI and or pit maticx。

so this is a way that we really able to move to seconsecond DDNN。

in our rabusetting and need basbasally ally significficchange change for for about about b。

that's that's whabeen defined in the australian earseve。

apple cut study has i mentioned is looking ted intervention with didighoditing in the real world setting。

and actually， we saw very recently tly addition of the real world dbritish sitting from the pival studies。

so i'm mark dwling。

his payoff。

ff is very exciting study， and this is a study looking at targeted consolidation with equitomm alone or incombination with lineerly demoderate taxmad。

now it's a bit word ally eligibility stustuwe screrepapatience， who were getting standard of care caty。

so patients the creria or standard care with was second line liicl， who were in circullar in aualialium papatience within undertook a circultion basn a as well。

a ccclinicc rec t we were paid。

this papatience had to be in remission by pit。

so patients filt line clinically that weren't eligible this。

we wanted to look at the patients who were in clinical reission。

but those who had an try to say a sisiathat refefefethat fefefethis susumit it this HH fefufully this this this this fefeto this this this a this， this is fufuly prevproconfeces。

they should in future highly。

now the block senanence and finstuis been a bit it a pit project of mine for over a decade。

now this is looking at maintenance。

check point in hibit after induction came on in a therapfor primary sentence and fina。

so just by wide background， we've had douor on the left。

we've had a gt t shiship leve had。

more than a decade， the the copy number changes in the c on MMMMMM ppm proprom proproprom invovolin bbking dic c um HH right right indiinforfefeccopininmc diagmum inforicum。

decided according to decisides receiriand and patients had able able of it。

they were maligible to move to the maintenance， which was paintenance with venvent cicso。

but the the studidesigsign was desigto padesign would be the study ditranspland。

i would say， over the pdedecade still optimizing how madiity of patients should move autographs should move away from radiotherapy mamajority patients。

but it's important and look at the real world datso um studithe to matris s appappto the the al decadaround around the a to to to of was is a desigsigwithout it a for padititions。

as we know is a very toxic intentive particticso with high traatic relapatiticity about to ten percent。

so stustill to to move in terms of identifying more effefetive better tolerable um treatments for patients to prevent relaland。

so again。

study has uh has recently had its uh um trdistant fuof that dda a stuof stustustustudishoruuh nicding from this data shortly。

on the yyyyle le uh fareing rerereduction of logical proproy researagain， i the on reprovireand left， that ppinssrereproviprovithat um is rerereprovii is on on sissisiinini IIIIA rerea II anticucular inn mmum um reresim of allogic across patitipopulation of madia。

i city is usuproviproviproviprovideddon briititin and kind sigggthat。

that is rereresim MM reinackground grouroup。

i rereini regrouing。

jelbourne with mt MH popostoking now seniah performed similar studies on the side of magalious studies magdicicto resisits。

the usuperplayum um lecular studies translational studies looking at both um um um mmare alialistubut associsociddand um um we are able to find some socisociations would predict responsiresisits ts ss。

the coral sisisisisiuum predict to the pppmermermerquresisistance in uusual plyers the remmplyso。

similar translation， which have prid IIII pripriffprofile options。

so that's enough from australian land get ghly now now stustgstudy h summary， which i will be focusing more another talks at other times um but the purposes of today just really read right stua， right？we've got uh long to follow up becoming avlowup to folshed manuscript so far。

uh， the the left lied manfolfoled soon after the initial long， the inty jarraan in matthology association in twenty four on the right is three year， follow up and freally around left with investiators ors， and the study time for jjney and inyable training journey and study journey。

just radibbriefly stggustudy is a ranandomise global face three clinical papatits ts relatrtrtrtrturand seven four， total urandomse two one， favvor ininof patitits intrananspliuh h inintervor or transplant。

survivial， if this just just fly abba little bit misshshow it because being shoshoing many other more condiinainof aaaaof of gengenaofand auaugragraphof domains and the other figger of genomainand， the auof gof of gengenaainofofand um majgraphrais inreining for the other more conventional reasreasincluincluinof of of of of of of of of gendiaofininactually， the majority other domains。

um in terms of the ascient demographics， the arms were very well matched dilion age around sixty eight years， which other mention before correlates with the austlation looking came up up the demerrelated disease es registry in australia。

um important tly， if we look about half way down。

and just just will how like this with lazer point for a moment here。

so in terms of number number prilines of therapy that had only sixty three percent in by found ms that had had one priperent。

so the majority of patients was a second line trial。

importantly， in terms of the number that were reficorory to the last blind of therapies of the purposes of this analysis that was defined as a six month cut off from the last doice of stemiic therapy adthistred， it was a kind of slightly different um definition defining time of of resources refactory。

but as we can say， here about sixty percent of ministence that actually been progresressing with ty six months of their prior ous therapy， these are usually poorest patients um。

primary factory， as you can see， low proportition pafor reasreasincluincluicictions study was performed um the time of the study being。

now three of of is up up is is great。

aaaavivivial vivivial AAA resurvivial al a prime ent reveral surviression。

free survival investigator um review commetee assist or so independent um review commedia assist fourteen point four months verses three point anonounces less patients progressing has on the overall survival。

now from these menu advances， just we can t more patients started that we can art to say， papatience ts， i expeexpect the the the inicaaaininct， the， the， the the the， but that is addicict a pleplereresisurvivivive i expeexpeexpeexpeto ct to inft the the treresn after survicles。

we can also see on the left side side in the second line in second d plus， as as we can say， the benefiting the second line is survivable survival。

and again， if we look at the second line according to their intersum response for getting same very high um durability of progression for raandvival survival。

this um time is just put any figures together that we can ite totogether hihighghghvvivivvfor survival。

but importantly， we look at the bottons uh was was was was the pleplete permission in in second d te perten perent in in seconsecond cor second DD percent in complete repent in perperts。

i still sasing the bottts， as opposed to the twenty thirty thirty percent。

sawas was ADD three point five persecond。

again， study did um trai s。

safety， not really anything unexpected。

we saw what we would expect safety file of addidition of degree of eedibody diyeesysysysyrrororoyvery ryicuwere predictable。

so bason stargui， i'm sure you agree with me with seeing superior overall survival progression for ace survival， complete response rates compared with the historic will comparative about gemomos in autographh in eligible patients。

most patients with a complete mission。

sion end tretrement remain alive and progression for two years later。

and that really does um endorthe commment glove it demos。

they potentially curative off the shelf treatment option， the patience with auautograph and eligible usurpreparity deal basc o。

um i will just d to that that ve i potentially curative。

but as i mentioned strally， we were very fortunate participate in the lady study， the face one basstudy dy first combined with feyond mmoing。

but the question from that enthat。

so we actually got even wrong ger data。

so a been able to noise patients。

and i ve been able to present that data。

so we 've ant been ongdegresents， and i 've gone to ability now follow up beyond five years。

but with patients。

so almost in remission from that study。

and just to highlight much of what our said is very encouraging。

but the question is， can we above the front line and above the second line to make this more specifiard ccare then look beyond。

so this is just a snp short of bemon to make the more drug contrigutes that uh either currently under investigation or have aaening alknow， the can ve ddcare。

so once we saw。

european meetings last year， where always seeing lonfolup up the studius study still。

and really， just a highlight that may evolve very rapidly of inding， the some of obof ous， some of the data on front line so far。

um， but a number of these studies that are iout out rereal quesation is sithe popopulations benefit。

if we going to low。

some of these traatments will benefif， they rebe easy to deliver as positive stuties。

and the question is， is majority of patients are going to be culed with those therapies。

but do we identify the patience that made arrive benefit if they studies our positive studies and really is the d way。

just ierapies that deal basy o。

we talk about it as a single disease entity， but it is characterize by significant genetic hieror studies。

and we look only so far back is the papapp。

they did a thousand one apaper， because a refinine the assification across the ation tion population， thankfully， as we refine the clasfications will benefit。

um forthank ing。

so hohopefully giving AA bdial research， and really just a ghghthat that that AA lalage to to to to the researarararsesearch and IA to arreseararh and IAI to to conorders。

the coordinate to colleague principal， investigate the the versity on the left， the crientitions。

and last day was yesterday as the deemprearthis ah a wonderrelater IH and i， the the the apologifor that the uday very perperto ah learn and listen to the subsequent presentations and looking to adressing sing quesquesch researmuch。

thank thank you for the induseerit。

good question。

so we haven't got that data for yet。

the samples for the paka's studies have actually only recently gone off to the commercial indoor。

so i don't have that daddy at available looking at the tizzism mable um anibration uh levels yet。

thank you， and we use the。

increased TCL or uh or not for the CTDN ic detections。

perhaps we can compare these results between these two units。

and and now we will。

go to the discussion and sections and in the discussion sections we have。

six，professors from china and the first professor is professor离近um from。

广熙university， i from the first affleted， the hospital of广熙maet，杨生鸟ok。

appps， there's somedifferent of between the。

program groups。

a professor is the first hospital of medical universities。

she is also dodoctor and mayouncommunimee working group。

and the third professor。

也是。

professor from first doctor and associate profesors。

and force fessor or professor one bei NG from iing ing人，hospital of capital medical university。

she is also chief physiciof of deof， the of of association， the chief phphsicians of this departations。

and，fifth professor is professor shooting from the first。

affiliated the hospital of social university。

she is the chief physician of department of himitorgy of these hospitals。

and she is also the member of clinical on college committee and also the chinese woman doctors association。

and she has all she has other many members， like a young committee member of hemooloc branch。

and the last professor。

is johaiing from west china hospital，四川university。

she， the associate director of the department of of mitlogy from west china ina hoititor。

she is the national eecuity ity from commeitlogy committee of star working group。

she is the member of of mechity committee from china association of medical education。

and welcome um our theseprofessors and professor young。

呀杨松养。

yes， thank here。

thank you。

thank you NA lot。

i just have some quesquestions negativity。

that is an excellent question。

so in that context for papatits， who were pit uvil viore four or five。

they weren't eligible for that particular study。

so any specifiwe've got there uh outside side， the intervenvenclinical trial um what we have seen what i'm interested in is transiy question wefor， those patients uh um pit positive for stditions。

so if a transitive reggression or eligible immediately for by specific or standard tive care in australia， which would be specific care or elimaa as a standard tive care or the pplus。

um we've got patient ts who are a vil for， and we speciviup so uh eligily be uh eligible ect， ct vible disease of the specispecifiso。

they they 're in in non clinical trial space to specispecifiexstardly anyway。

and if live al。

there's an therapy available do as have lan n dda a not a larlarical patients。

but i do agree with you where your questions hting， which is um we go back to the autographh that was was tient with positive vity ity。

we back to the porporgrappadisease that was driving with positivity。

and i truly do believe where you heding with your quesis that if we can use MNA show， they've got CDDN negagavity， they， we can actually be stand something a patitits and repeating that day day。

and i of we do say that that olution have going going um i don't have data on a meanful number of patients。

and a patients who are hit ACTDNA negative subsequently go on to become CTDNA positive。

i are perof of the dda。

look at CTDNA follow up on patients presprestitipresent on papaago。

and unfortunately， and that studia have time。

and i guess， negative predictive value at the day day was that day， that dd'd NNIDDDNTDNNN canneditive。

but ououlououldn't offering in your offering even if they are in response。

yeah， actually i really don't know if we just do this kind of thing will be helpful or not。

i think it's a great um concern about。

i really want to relect to the first line treatment with the first really specispecially。

they receive the party seof myah。

i really want to release， not only patibut also myself， but my worceryeah ah really want to this rethink ah II think， yes， maybe。

we need um more this kind of parammeter to uh just just describe which kind of patient。

we really need maintenance， and yeh， that's great ideabout。

yeah， thank you。

thank you very much。

and the second question is about， you know， the gloval mathe plus uh are ice， also the accurate of rice。

uh， you just mentioned about uh， there will be a very high uh retionse right， and also see r right， then bridge them to the autoof transplant。

so i'm very curious about that。

uh， why we need to breach to autalof transplant。

why not the carty cell treatment？

excellent question um sorry， i think the main reason currently is。

that question that you ask， which is pivoo who needs a cater uh in order to be cuit in the second mind setting。

and i guess， conventionif， we look recently wesisaid if we had someone who was caligible， that side were a relalaso， so wouldn't be automatically beyond prosponms would automatically be eligible， but carin australia， but was autographggroutheis that very difficult group if they are autograph eligible group。

and so the question is。

in australia， now， we are moving away from mohotograph。

the patients who are older and frylla。

the ones who we used to have to push to autograph because otherwise it was gem moxand paliiation。

um but can we try and get bita long term cuure right in the car ineeligible professions althose who progressed after car and actually deep in their response now？

the question i ask still to myself and others when we talk about using by specifics as a bridge to catay。

is if we intend to do that for all about patience。

we just need to remind ourselves of the。

predicted， or i guess， the number of patients who don't get consolidated in the epcorore deal， basic al studies in the staarwy studies who achieve a durable， long term response。

and and when i first heard colleagues， i think germany many are very quick to move to。

bridicing。

now that wasn't because they was diwas is a studies。

okay。

thank you。

and uh， i still have some。

you know， question about MTX。

you just mentioned about matthotrack set issue。

yeah， uh， we have more and more data to um demonstrate um high dose matthotrack say， cannot prevent um ud DS mma。

but we still uh have this kind of recommendation in SCC and uh anything in any guidelines。

so do do think about it。

how uh i just wwonder， if if still still see c matthotrtrx ate to prevent um if you still use this involvement。

yeah， great question away from the the maorvalue ue IIIA to roup that be uwis inin gwing。

design around dodowith activity CCRS sing we we can stto to erexperisition i posiah。

ok， thank you。

thank you very much。

thank you。

um thanks for the giving and a developal and and and and and the tretrement DD changed AAA treatment or moa time time for inperininproretreatment aggrestrevely fordel after the first popupera and the first for the pertion and for this。

thank you。

it's a great question。

so it's just riking about aa。

talking about paatment ment transformed， uh a patient ent papatious patient ts parenform paparesaformso that had patient of these patients as um um the survival patients with transform patients， as um not not treaaatent apatient said， we had a public preous papatits said。

we could say that that in preataof and eraent said therapy did as well as um not front of papaforent。

we who had previous treatence tended to be progressing more and more。

in australian context， it's a very complicated discussion now around which of these patients are eligible because our via um worfor for reimburassment religibility for catty in the second line。

specifically stated retux a mad with antrrecycling containing therapials similar。

all lard selelent ffirmer， one of the big problems we had with these patients who had our shop for their front line vlecular in funmer， then transformed。

and so we couldn't give them the full number of cycles of bantror cycling。

so increasingly， in the australian contest， xt re's， more and more of these patients that have been moving to uh。

treatment with artaor by specifics。

transformation。

and that's largely because a lot these patience， ts， other ones that the twenty four transformations。

and in many ways， we think they probably know quite ten。

the clination will say， look， they had a higher that they had multiple sites of highst disease。

they had some areas of bidon on their pp， and i believe acthey had transform disehad transforms that they had have accapture the area of classic and didn't capcapture。

so many ways。

i would justifiy the say they believe the patialready had had a hid d。

the area had dive the p disethey。

they their ligigion their standard of fronseconline that it of the way， the paperer d that and diis the hard when we've got someone who hasn't had， they， i ved large llfront and has received their shop。

and now wwn two or three years later， often were having to give them another line of intensified came o first， like a。

AJJ payer， arse and and him doing early response to trying， get them to buy specifis or caarrely。

uh， thank you， a professor gallgory and。

由于我我觉得我还是用中文问，可能会更。

i would like to ask my questions in chinese。

i have several questions。

i would like to ask so bfirst sly。

my first question is like i've mentioned for molecular subtyfics， like a be seling fora。

it's a very important。

so so very first question is like larvery molecular subtype may benefit from by specifics。

we have datata to suggest my first quesptime may benefit more from by specificance。

thank you for that。

excellent and very relevant question， uh properct。

so i'm short answer that i haven't seen the molecular subtipping data yet or stagguitions。

i expect that is going to be presented um in a future mating um。

what we are doing in the australian setting。

currently still is the failure uintertering of um drive through the a lot of lot iium ah not a of of of the giiof algassiy um currently um i'm not a combe， some um data comcomout um um not not yalpublished um but ah ah be aware of um not a comicalgoriththum um that should make it a lot easier without to ium， complicated algoriththum um yeah ah not not AA easium。

molecular sub type that actually uh benefits its greatest from uthe bus specificc guantety ty is one thing i will say say， finally in quesquestion is um if we think about in uniite therapy with um check， check point hihiit it as an example。

one of the， i guess， areas we need to be mindful is that there are copy number alterations。

at indict or socirese rerese to check get that trbof different research。

到ss thank thank you，

professor gregory， i am。

我的第二个问题是my second d quesis we we that um combine stustuquesbenefit combby AA combine what you choose to。

i ba bafpha。

exexcelent ent questions。

uh， i guess， just highlight the front line study we have saen um the reference to the positive uh primary point of here lium。

we do not yet every intertain pastralians。

so reis ertto um taffline。

uh in australia yet without chop um so we don't have that that h that practical real world use。

yes， in australia， um so similarly， there i would only be referencing clinical trial experience in the front line。

i personally did not have any subjects nodid my colleagues in melbourne。

that said， said in tratraany progressiafter a tflarch p front line。

uh， what i can say is i have traded patients in the relab sitting who had come um referral centres in the star glow who could not go to。

carty because they were sitting on tatain negative， having been received tyfficsitamat containing arrangements in the ray lap sitting。

so it is a real phenomenon um。

how h sithink。

事实上现在目前在中国，

因为费用而确tually in china because the cost is still very high so far， we are not using caaffline in the first time yet。

everyone。

thank you。

thank you。

thank am china al al examamof examamamand s ins NAD question is。

lingful size will their response be lower？ thank you。

again， thank you for these excellent questions。

i'h try to rerember them quesquesh。

so the first question around the number of cycles of therapy， obviously， what we have with a third trial design。

and we know what the daatteries when we i in the clinicsittting without patits， we know enenitthe setting without patient and depermily， what would be what we know they should behave like if we give them little therapy。

and the reason of desigsign， a click cycles of the RM mox has been the standard of care。

ftherery is the new benefit in the study， the monotherapy setting duof cycles um third week schedule of a line of geermox to a line with the third week schedule of theramm， um a third with excellent and the cldo us this a lot and say， how do we know the these patience ts destant？

to do well。

and when can we stoart the escalating？

the clinical trp prode MM of of jgmox althe patience， ts inllering uthe adversifito to to m mos specificc ininini h to recover them。

the tological toxiccity bealonthe althe weeweeweeweeweethe， the the three weeks s。

oh， SS permit ethicy continuwithwithout jammox in noiinstances of toxity and clinicsetting。

we don't yhave enououdda and the glad to the the i because III， because the pronc and saying， if we can identify data and the i alalalalthe three weeweethe， the ycs when the olathe， the the weeweeweeand althe other gat， the canaics， perhaps the chanchanges。

but if the loics perhaps。

the timing of the pit scans because in the clinical trial will performed on ytrtrfor and then later again， the treatatment as we know in the real al world resuin in former， we often bring the pans anlier。

we often bring the ininaround we reresss ve to taving a sub up to reresponse someone that we might have move to third line carty。

if there a second line carty eligible patient prince someone who progressed after to uthers from ererp p。

so the main questions wewe reing ing them around earpression。

when i was a moinly investigator in the face， one mogenittumam study， we often met in the safety calls。

and discust about recruiting patients to modeitable momonoerapity was twenty twenty negative。

and initially， we were committed to do so because they was a twenty pertitiand， the maltiinaby mouse moatiin oureregative， so showed um situation of seedingly city， twenty negativity。

we still having responses in some context， um genysizzlaw and expression sion。

this wouldn't um detected able convenvendiagnonos in the clinic。

unfortunately， mouse， apative IDTA number stustudiwhere。

they were permted， whether a inintias the permitted。

er eh， h had a meeting for response， uh， if was city twenty negative。

so IAA insee our patients of progression if they are。

twenty negative， we will usually look for clinical trial option or uh a treatment option that has an alternative um and tertatiarget specispecitray。

i think that really the other gap in the question， according to crilimbate ansimilly ly ithe， the question have got a crime immune。

environment for activity of by specific and one step further， is there a difference twtwen en， we might benefit from caty。

this is by specific r。

they overlapping。

so you've ask the perfect question。

i don't have any data for it。

are they study being performs performs II opsing。

a lot lot of samples to look at the characterized the tayelling infutrade and and the perspectively， which patients might be benefiting from by specifics。

actually in our hospital， we haven't perproducting these kind of examinations。

thank you。

thank you for佩是。

好，谢谢张爱玲教授。

那接下来按照顺序，我们邀请talthank you professthough。

now i'd like to invite professor亮wleto join the panel discussion session。

thank very very much。

thank you for your excellent talk。

ether doctor wyyg from toren hospital from ctor close study。

i am doctor jmars s seconsecongragraphh t percent。

i good result。

now was the current guit current rellt preprimary factory or earearly relatipaor be rerepaent orso。

i want to know about excimpion or primary factory or early relafacpatient。

would you choose whether we be grapt jmarx i am docurcurrent is repricurthe patient felt section and a graphiit after current failure basically reretory。

or will be only around thirty percent。

so if the pavation not receithis treatment is better， like pecompapaation， thank you。

yeah， thank you for these excellent questions。

and and it's really reassuring that you're having the same questions that we ask ourselves that really the gaps in our knowledge。

so for the first question， II agree with you that they are going to be a large proportion patients that would be eligible for both caata and by specific combinations that are likely to get benefit from both now in the australian setting。

still。

all reimburasshas ggbeygone beyond the alligibility in the auaustralian reimbursement， asienans need to be auaugragrapand and auinegabable。

so the follow up is larlarly on in facfact inllve on the fact belt t。

um i think the main question is， how do make make what what ak can we use to say hospitto benenenenents these bspefit from to follow up？

but they ququbit AA little bit ititdon't don't want come come to to to to。

i ve a example of loolooto ininatof to melbourne that there is a lot lot datatof ininsisiof gogigireasand withwithout， a single anmission adadmissision scheduled。

and dithink think i innna a dda， a deicick to to icto to and rereresetting。

this still a single le prosision of msigeand， and think think they inatatof of perinforsiand and IAA single le god admmthat。

there is a lot of real al use。

lofajmos datand。

so we'll get that data and will get the jurability。

but at the moment， it's just what patients can access in in australium， we do have a large proportion patients with such a big geographhiical country， and a lot of patients need tratravel long， long way， get get patibasso。

so a lot of patients are leleting h glove at geammoks， based on unwillingness move to a diffefestance to be traated。

um now we we seconseconquestion around papaents。

we progss pogepatits。

we not a big geopatience well， but offer the best treatments for those patients。

we offer clinic trials where we can um we do have have credm up the third line as well as low fit geammoks in the third line。

um we will offer them both to patience ts quto about the ccons patients progress。

ss very early after often aearstill， the enuropanic side of panic。

and so therefore， the gemocs is not that will tolerated there。

the ones we we drop off the papamos。

um but in terms， don't have the ability to investbcombations tions or arararms that dibefore before that， i inof of what i stwhat one， what strateto in saying if there is more specifics currently。

因为我们中心就是过了将近，because in every center， we have already done in two hundred cases with a courty sale therapy。

well， a lot of the pictires。

they will they cannot get the long term uh benefit。

but using the antity disingle uuh， they caution reaching the CR is very low。

so now we have the combination with APD one。

anybody so still。

for some of the hidden carty cells well after using of the PD one， the carties they can be enhanced。

so we see some studies published in a blood cancer journal， just for for the d one one anybody to get with recarses to treat AA visil。

they would be effective， but is still maybe only just we use this like this kind of regiment。

still， there are some portion of the patients they cannot get a very good responses。

so if even we get the a level， certain level of the responses， we would directly recommend them to receive their allow transportation。

so these are my other experiences， and thank you for shering。

thank you， and i do also younger。

info traying taso l milar look like and what can be done to try。

not regulate those tastl responses。

whether ther is check point。

he he it rather ther sbut， and thank thank for uuh。

really interesting uh approaches are useful。

好，再次谢谢二位的讨论了解before your discussion。

and uh then we would invite ite a professor shooting to make some comment and answer reassome more questions。

thank you。

thank h。

professor for your excellent presentation， as we know the starglow traexincluded DLBCL transformed from england， land forate and high gar gatforand。

what is the real world world of of grograpphit map based main painforand？ are there any available data？and my second question is， are there any response rate for the TP fifty three mutation positive sub group in the star grow study based？

thank you， those excelerrellating trtrforform diseases first， combined that the other other al studesign largely due to FFD ffeeback。

um yes， they had pasision transform disease。

they they had decisid that that h， that ggly al al。

we did ly ly that DD that um that in inone bstustuthat， we performed the two other sideof insidedesis， the the DDMDDDD， the the the double trforforform。

ms， the safefeand is had papatience m diseash。

uah。

they did look at the double hits as well。

um i say no double hits if that double hits of had perpermed and no dououble it that did did the stustudy， but they were larlarge forporpatitience。

ts dousisting had not been perding um as don't have pertisiin double ble fso。

so that tells us again， that i don't have that data as ha't seen the proportional patients according to have hadid， said nin double hits。

um but we 't say that that one of of perstudies um HIA， they did did the stustubut um but larlarlarlarof profortion on the difile。

so withnot perding them。

i don't have that ddforso。

so ah haouble hait inffile。

so i don't have that data um。

either in the monotherp o relalap setting， have you been performing that routainely？do you have any vocddata to say how they are doing in the the setting of by specifics？

thank you。

thank you profess。

非常感谢，

我们oay thank you so much for the six panels， st and professor grareg for your very detailed answers，

我们well next with我的invted professor主席，下一个环节。

greg， we invite professor ged to moderate dissection。

王王王丽主任那个后面由我们主持人来，

好好行。

好的，谢谢。

也再次感谢王林教授。

ok，

thank you again for your sharing prefeter。

王丽当概，这是我们的。

well， we have adjust uh listeson to the。

canknow speech by professor correct。

and so we would enter the first second session next。

so we would invite professor joapeite from teniny medical university cancer institute in hospital to give us a the topic on ah how i treat the different， a loor to the opbesl in young patients， professor jothis， the m， the associate profesician and mal that for the medical university cancer instituin hospital。

so next that would would get a floor to professor job to the our sharing。

ok， well，谢谢主持人的介绍。

那么今天跟大oto，

thank you for your intduduand today。

well， after like to share well， how i treat to um h that for the patience ts with the BCL with the the BCL acaca pamenical practices，

this is a very common icing tight uuis uh young patients，

how to treat them。

well， actually， we can see well in the general population over the obusial tight。

certification by age， well， actually， for the BBC away relatively this is uh disease that frequently occurs in the middle age， the ouders patients so care for the median age of onset is over sixty years old。

so for the young patients， they just account for the small portion of the whole population， but i believe that in different centers and different hospitals， if they have different patitials， maybe in the grocerster's units， they would see higher ratio， the middle age， an order age， h patients。

well， actually， we would do a series of evaluations like for the regular evaluations， lababatatory test and also iiging test as well as a bommerbiopopsy。

and many of the center。

we need need to do this NS well for the b opb c。

well， we have the many patients also the bidiergy for ftisity。

we would consider the presenining of the ertisity to for the freezing of the eggs， or the uh biopsiity is many of commoperperin， many， the opsior or the the the l of ditisity or the the of the diaunosy puncture and bioppoity or of opsiwell for for the the BP sy and aggassiof biopsity from the very ginning， the biopposcollection ction， a process of the HE staining ditisity。

fish on analyses and NGS to do other diamsses for the OBC es and in adincludes different types。

well， in addition to OS and also the the we have the different typpes for the for different pop types。

well， actually have have different strategies to treat them and acdifferent DAC of of the system， and also for the DICO for the different proprosyimagi IPI evaluation system and also for the AIPI。

well， it is basthat well in rea。

i genconnical facctors to do the different tification。

and of course， different different， a lot of different different process like imaggenetic tic tees。

well， it the faceors well in our center well in recent of well for the DLBCO。

well， the the for earearly ge mamainm study or the progonistic models and the follow ing treatment we have done series of explorations well for the TP of degree， but actually， for the politicians different exexosms， they have different values。

well， we always for the t。

ty ty muittions is acalso for the different gnosations， like for different different exosms for the and and regifor for mamatius是比较，

差and have of of patient， have multiple mumumumumutions tions， and for different patients with the tititions， they will have ire can be burden， higher， um mutigical sor。

but for different dial sdels，

we thaking， they were also have for for different and teitical exexoums。

will also happen in the adstanadadanananananimpimpimpimpreredut TTTV reduction and chemistry。

we can see。

uh sometimes for different involtion involved， for example， for primary perfficficfor for inficficficffficficficinininfficficficand and of courficent different suffficficent for ininininsufficficficand and and inand facand different different generation example where。

一个研究的一个终点trying to have x comine with uchrop uh to see whether we can have better pratnosis and for lowest patients like。

patients who are IPI zero here？ we can see comwe ing comcomparing pawe we we we looking at。

we are aaprecomparing for not see sigsigficficpadiffets ts for cerdificpapaents do do see。

pollo are ship benefit and about ourorigrestufor patience ts， a ouc sibsiof of sisitive rebble exdises and enefit is not very obvious。

we also have some other studies， ube bsudidiis resiand。

we also have some to double exdises。

we we also subatient for primy survivivfor survivand。

of course， in terms of the design of stuof for pfor is sisiis。

we also outcome is still positive to。

a part是主要重点EFS have en benenefefseconseconsecond benefefit s some bo MSSSSMMMSSSS wever rerered d ready been covered by medical three perent ent now。

also show that was for IPI young hiorbcombbbbbbba s coca bbband。

i also have some bpica combbbalso also combstracominact。

你整体的治疗结束的时候，

这个患者的整体的这种prime y。

point point here， we looking at the prime impoint results， and we we used。

the CFDNAXC primiate stuo s are are positive。

tive。

patients are RA sisition treatment and CFDNAA continuous ous studus RRSRR ally low low， usually SSCRR also conconcting large stale primiate studies s here。

this is pplus as sigdisic plus al and see c dila on one stustuc stustuo genr tic subtyping select ting and RRP plus s retaping result we can see CH plus s can significantly improve prir stals most RPF sienent。

this say ped a percent was sixty three percent and later， we have dly guiden some five city。

here was RCP plus x pola RPX comparing to RCP prepreprepreous PCP。

here prepreprec CR here， prep preprep previous VCR to explore the treatment asalfor。

they fpreaameasasres alalfar to find some patient are using right now。

are not show satisfactory inciciresusultions not reduce ce for CNS retits， but but inininpreprecic ininfrom probut， but but diffficult flllerroinbut trewe sulogical anchnosis， but preinperinforal patients， but we but posstill logical diagnosis。

to the certification by using fish and GS。

we 're still trying to better studify our tient with more precicicices， with more precise tratification will have better treatments for double hiit patient。

we are still trying to use so double fiy patreatment tretium h specispecial pof for DRBCA like primary CNS and ma um primary dia specima specidium mema basically for special tipes。

we have a specific treatment method primary， special c atatmethod d et um majority of patience are DRBCS for HH， not other wise specifiy patients。

so we will be specin MM sim m doubetter CNS for mpenence more。

we will do from mardo MMI ini papaents。

and we also have our own。

we need to consider IPI score and RR to have。

we inconconsider IP papaents ts are papatience ts。

we abably prps SRR lulus， s and whther ther。

they have。

we considertretreatment patits ts for i pps s are patients prababpaptits for r ps s，

and and we siderfree treatment ressuwhther ther。

they have。

change are looking for a guideline or five delt in year， two thousand twenty thousand， twenty five， five， da for of of of MAA for PP。

the first ererperent， and we can see compapain our ins ST see。

we see have a perpers is better than accand。

we can see。

we have a lot of papatits ts MCD for percent and common for pain for for polabthe。

the erererpert SS siin， our sperapy。

has some improvement in remale。

there are are are stuis dimungoing。

but actually is still high risk and also liver function and also AAACILL。

and and and here very high ririsinand for for CCC clel l。

so ICCCCS patience。

so so AAACCCCC lel and remmand and h this persininjection for CNS。

so far still and ounounfevovolinvolvvforalforflcompcompmale invovoacforvery high。

一个图had we double day think very much。

好的，再次感谢您的。

ok。

thank you again for your acts and sharing and presentation。

well， next， we would enter the panel discussion session， and we would invite several panels to have the discussion。

and of course， we would welcome you all to riithm questions to the presenof by professor job。

firstly， ah h produproduction of visa patients。

well， the first pancicial mespital of a provercial hospital from the shangti of deapartment meitlogy from the central seconephysician mater civilisity from the复旦，大学附属in professor joysician from the shanghai geoerics memedical center of the pa of sian hospital of universition was the socisociate chiephysician acting hat associment of chemthology in shanghai jervincial memeical al centre，来自广东省第二人民医，an and professor jcy from from the onong second provincial general hospital， as associal seconue proysicial general medital is the second provcial general hospital。

医科大学附属医院的，and professor tly sa from the phillia hospital of inner mongoliamdical university， the true physician must ter sicipervisor department of humidology， the faililited hospital of inner mongolian medical uniververity， though。

first， todauah for today's for today's uh discussion session。

well， firstly， would inite the professor jnnto to raisome questions。

好的，感谢会议邀请。

ok， thank you for invation。

and also， i would like to thank the mothership and conpress a job。

we were acting to presentation about the discussion on how to treat the young， the official patients。

this is very reinvenent ent enenent， and also have have disexperiences to。

we have a got a lot of experiences from the tenging tiimor hospital here。

you have introduced the certification as well as experiences。

and also the have ririsk the opbesial patients we can consider the escalation of the treatment， but for the patients was a medium to high rik al levels well for the polar uh polar chop。

they would benefit more as well as a experisient from the discussed as well， the patients some of the data well for the grapy to maple entering the first line in commenination with a medito the theraps。

and uh， some of the explorations and the clinical al didies from high risk papatients and also an introduction of a two， very successful cases for their treatment experiences。

well， here， i have a question to profess job。

well， actually clclically。

一些we always have receireceisome of the younounpatitits。

they have the TP of three mutations。

they have the significant TP of three three mutations， but their IPI score is not that high lesson。

well， if we just the want to do well， the first kind of the patients well after the first line， polar RCP well reaching CR。

well， if we need well， do the all auauautrtransptitions reduduthe risk k for fufuture relatiations。

thank you。

ok， k， thank you for your question。

well， indeed， well for the IPI。

well， i think this is the most important scoring system， but the chclinical settings well， the IPI greater well or three。

well， i think that is the auclcomly use the threatwd for some of many autrclinical trials。

well， for the i this time。

well， actually well， do what it is a predict for the proor ggnence in the ah clinical settings。

but here we cannot have the very precise。

selection are for all of the patitits ts for the patients ts AA of of lower IPI。

well， actually， we would prefer其实有PR图片。

well， even though have to t be for deprivation。

well， in the first line， we would not do this uh auto transplantation， no matter for the the LBCL。

or some of the other medications for patients was the TP of the titations。

well， they 're insensitive to the kems s well， we may have have first repeexexploration oh es for for the eperation ation， not i well， we the the proication for the poror， a ininreduct， a inintroducof or the kemmowell。

this well， ah there is repeated explation ation the proposces。

okay， thank you and still another small question。

well， i see this way is， well， you have introduced for the introduction of a goal fiem mab。

well，

acacwell uh for the experation studies i，

but we have the studies for the zoo twelve for the series of the zoom studies for the high rik p studies。

well， the the experoration for exploration。

或者卡替放在高危患者的一线，不知道就set it in first line。

well，

if you have have the very optimal optivitic tic comments for this ululterly high risk patients in the first line，双抗和challenge治疗to have the application of by specific toanyc。

well， i think this is a very challenge topic。

well。

我想阳性的结果应该well， i think for the positive results。

well， we have a great possibility to have the positive results， but it is not necessarily to change the clinical practices well in the future for AA al results， but for the silar CT， but we have get great positive results well in the most suitable population。

well， in fufufor have have great， great pocussion very hot discussion for what population that we should select for different center。

the we have a different sereria for domestic c for different， different， different reselts。

but in the future， for the future matter a specific or the glothy etiical or curties， but we have a great possibility to get a positive results， but we would consider not only for the positive results， but it have more benefefpopupution tion to enter the same policy or strategy。

well， i think for the benefit populations would be more important。

even though the IPI is too， but also they would benefit more for for papatients out。

IPI three to five before by specific anybody like glophy。

well， i think like an epical well for patience， IPI graers and two or graers and three。

well， they would use the arregement。

so we may need to have a number precise a certification of the population。

to let this third puty ty way have have better benefits unless well for some of the treatment in the future。

well， kthank you for your fefethat。

they can need repapaenso。

so would not only see the generor or of s repao ence。

so we of the factors we need to consider them。

well， kneed need AA sifor reexplinpaooh。

ok， thank you for glaand and would invite prosito。

ok， thank thank and and inso glalad to sten n this this feor。

we need a young paation ation well for a young patience well for some high risk patients。

的一个疗效的评个评估。

we need to do the evaluation of the efficacy。

well， care。

i have a several questions for the patients was the eleven cumuication， or was a great portion of LBCL。

how would treaton five to eight well for tretreatum was for invasive LBCC high gregreat DLBCL were sisimilar。

the pasitions for the patience was the cycles to evaluate the efficicacy。

well， if it is not retiacy or would adjust a transfer the curty or by specific anybody as thirty possipossifor for a small portion of a population， how would you treat them？ and if， for the first case， i the a great treatment reament for a commotition of apollo。

well， actually for these treatment。

well， for a gencuk patienwell， what would would retresomething or the other way around othink AA great atation of first first ly， the second question， well， i ingeneruof speicment。

well。

before the transplantation， well， some of the medications they are not available， we can do some of the subsidies well， just with this， this cases， the specific case to eapola。

and for second question for the DOBCO well in the first line， if it is ACPR well to change or not to change。

well， i think this is a permanent to question。

well， indeed， it， we have some questions。

well， if it is his only appeer of patient。

very good一个paor， or if it is a very good appeer patience， ts， almost CR。

well， maybe with the consolidation of a two other cycles。

这个患者可能他后续for this patient may be follow that很难能够获得一个缓解。

well， it is really difficult to get to the remission。

but for the DLBCL， it is not like the FL不可行。

but but for o个，个者well是一个，

if for this patient is only appear and also with the complication of for so many high risk of factors。

well， it is didifapply uh persk of rectments。

考虑患者重精验。

also， we should consider the economic condition of the patients we would consider the transfer or shift of the reference owe can choose by specific or the curty in the first line well， already reaching already ready rely to have to second possichoices to have the progression of the disease。

ok， thank you。

there's some more weltions。

ok。

thank you and re's a welwelproprogress or a specie。

well。

非常感谢赵教授带来的就关于贵中心的一个非常好的年轻的，应该说thank thank thank you。

so much，

因因well acactually risiility for this medication。

well， then currently in the high risk deal BL patience， ts， well for pofintienence。

well is is very able benefit。

well， i think in the young patients well for data， a， this is a sia。

可能真实是。

we still need pansupplement well from the real stustudies， if they would finally bring well for the benefit。

currently we observe that the benefit it想，就是请教一下，

就是赵教授。

因为我们其实在well actually中期pt的时候，what we do the interrest al pt analysis，

we would need ythe patients ts the score well， for this patients acactually tually。

well， well， is this possibility。

to have the false positive results。

and also there re's a possibility that after they continues treatment of the original rewe的。

其实我们有更多finally rich HCR。

so currently was a lot of the detection methods and is ACDNA。

do you think there's a possibility？ but this， this possibn or MR dedetetion？oh， the the the NNR treatment。

well， i'm not sure if you're centre has such such kind kind of secity is that we we have a small question and also acactually in。

also， there's a treatment of these normal IP conscore range four to five， but not double hit well in the error of new medication for to ty is we think in the the position of the transportation in the first line is still necessary一的falrellthat。

we do we sual that the consulilaation by the transportation。

okay？ thank。

before your question will actually that， firstly， no matter for the medium stage or EOT。

well， a lot of them， they show the score or even five。

but econicical practies， i think this is a really difficult topic and an econical trial。

this is to fa， easy and and especialincluinclua of patitits ts ts。

and but but at end，

end of tretrement that they not reaching three or lesteenbut， but of the the city design。

well， there is a stoppted and several comlater。

well， maybe they relaaces on this kind of patitits ts， but think think the economical practices， if we be the patienes not reaching ststard deff a three。

so maybe we would have some updates of the terrictic models according to the evaluation of the afthicacy still have have some shortcomments well，

even media e。

well， well， even OTT。

well， they eal trial this，

the。

knows for the leverage for the leveration is a great possibility to have great inforlation。

well， this is a ratively easbut， but of the the posipractis， we cannot get get the pothology very dificy think ina icly ly。

so of the clinicics SYY， but but somesomeof the consitions，

we have to make a decin IA，

the challenging stustuuvery very chengengthis in this MRR。

well， of course， we can use this in clnical studies now withwithout good ststard。

so if should we to ADNN， that is to AA clnprpractii， i have we we not get it so far still very difficult to change the clnical practice。

so what should we do？ i think， sometimes we need to。

really rely on lot。

and also we need little communication between doctors and patients。

we have lot lot patients was a compacacis a very ererapp that sisisithey they are are are is is is is asir， sir or siether is is sir is is is acacsit that which acaca or who they respond， and then achieve response ent paent ts， they were score。

still very high。

ais is sisisisitisiis is is very， very ato that that's。

MRD may be a future direction。

but so far， it's just limited to clclical study dy dso， so probably not enough to change practice。

and then about transportation， thank for some young hispatients。

we will do transport， but inindeed young， very big allenenge and different new drugs for pallenbut indo be new drugs。

they are enrolling high sk patience and longer ing trtrspsptation tation。

i think for young patient transpsptitation practice， and then for double hiit， patience ts trtrspond has trremoved from trtrmenenso。

we think about reducing accispentation。

thank you， doctor job for exaccident tiso， and thank you for sharing your center experience。

and thank you for sharing um for for some younbig patienent。

for the LBCL， your talk talk sometimes， when you use informaafter treatment， lausomething someit be dificficlations， but treatment and flamations eevficy eether is positive。

poounperpatient is is younounpatient um。

we have changed the first time negative ding UT。

and what should do trethis treatment selection， these patitits medical rembversement factors？ what would you choose？

um what resuse what you choose se treat this patifor， the RPCU usually， usually it ubecause specis CCRRR sininery specispecispeciapapbut of of because for specispecial app of of se SCRCSSSR far， we don't don't have a poc RM ererererererapp r is SSRCCS。

they the thats or。

for transforer radio ererapbut，

we don't know about benefit now for a lot of some speciale menting inare bitness for two apbut siwe not know about result， t not dic erery inmspecial mmale。

the ing patients uuting their PCL。

now we not not doing nererapy assimers were need inmbut think not doing intensified treatments if they can tolerate。

most of our patients are young female in are papatience ts tresult fornot do were reinininsumts。

i think we need to。

we need to。

consider also about the medical embarrsment for simas DRBCL。

if we are going to add BTK hahabiters， do you think it is memey mad DDDDDBTCRBBRSA buum？ maybe it's more frequent for simms DRBCL。

yes， for sims involved DRBCCSRBRRC for like primary testitic al primary RR primary DRBCC。

some of them may have for CP sometime ARRCC or pola RCHP combine with DRBBC or personally。

我会更加倾向，以达为power， wer p为为础础times it。

we use一个一个一个一个基础，如果说这个患者经营状态，CHPI say i say foundtional treatment afplication is affordable and also relatively fit， and i probably will add BTK。

为了兼顾这个BTK，

so这是这probably will add一个情况。

so that's my overall consideration for signence and dia consivement。

we still use DA porch h， but of course， for very elly patience ts一个个据。

we probably will consider other treatment regimen and sometimes。

这个特别大的高危的患者会有for very high risk patients we。

就c三零胃，因为很多患者会c三c三零的一个阳性。

the city thirty treatment because some often have have city positivity。

thank you very much for the discussion。

and now we going going enter into the closing sturemark rereor and and reredeorteteysyorrefeor todayor and chinese， i rererereoror for deyyteteysor profeand or proproreor meeting result。

临床实践出发in our center will have have shshfrom from perperperctits about inininseconinfor indeof deinacacding seconseconseconsecond d acacacacaceeand。

our ainment reatct results。

international meeting for defuse lot be sound in former， in particular great up reflective patienents。

we have more experience sharing。

i hope in the future。

we can have more meeting things like this to have opportunity to talk to our overseas colleagues。

finally， i'd like to handover to professor gargregory or concluding remark。

yes。

thank you really eling s say from spopopopopothe sspopoabout。

the deof s data that is interactive discussision。

the same classes becoming available， but we have ven't the same questions that we have vendcinal， triand and II， accusing rerereargroups and II communities， and and rerein。

the rereresererereseararrerereanswer ing lot lot lot quesquesthat that i researarin rereseari and。

just my lighhave far away coming， so thank you。

so not shingdone and good noance。

some。

thank you again for the imvitation to the long and contribute tonight。

thank you。

thank you for the professor， greg and all the professors onlines， and perhaps we can meet to in some。

great conference such as一号and ash， and we can discust furthermore to the collaboration for future。

thank you。

拜拜。

thank you，拜拜。

好，谢谢大家。

那本次会议我们就到这束，everyone下期会议。

now h。

we have concluded meeting for today um for the next。

we still will have professor gragory and professor biile and professssor。

next an we will join next meeting looking forward to the next meeting and see you next time。